Satoshi Konagai
Direttore/Membro del Consiglio presso Solu Therapeutics
Profilo
Satoshi Konagai is currently a Director at Cleave Therapeutics, Inc. and a Director at Solu Therapeutics, Inc. He is also a Senior Investment Manager at Astellas Venture Management LLC.
Previously, he worked as a Senior Manager at Astellas Pharma, Inc. from 2015 to 2020.
Mr. Konagai holds an MBA from the University of Massachusetts and both undergraduate and graduate degrees from Kyoto University.
Posizioni attive di Satoshi Konagai
| Società | Posizione | Inizio |
|---|---|---|
Astellas Venture Management LLC
 Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Phrama Inc founded in 2000. The firm is headquartered in Brisbane, California. | Investitore di Private Equity | 01/10/2020 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | 01/12/2021 |
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Satoshi Konagai
| Società | Posizione | Fine |
|---|---|---|
| ASTELLAS PHARMA INC. | Corporate Officer/Principal | 31/10/2020 |
Formazione di Satoshi Konagai
| Kyoto University | Graduate Degree |
| University of Massachusetts | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ASTELLAS PHARMA INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Astellas Venture Management LLC
Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Phrama Inc founded in 2000. The firm is headquartered in Brisbane, California. | Finance |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Health Technology |
- Borsa valori
- Insiders
- Satoshi Konagai